Niclosamide and its derivatives for use in the treatment of solid tumors
The present invention relates to novel therapeutic uses of niclosamide for the treatment of cancer. In particular, a combination of niclosamide or one of its derivatives with an alkylating agent is provided for the treatment of solid tumors. Moreover, niclosamide or one of its derivatives can be used for the treatment of solid tumors characterized by underexpression of NFKBIA. Finally, the invention relates to diagnostic methods for determining whether treatment with niclosamide alone or in combination with an alkylating agent is suitable for a cancer patient.
1. A method of treating a solid tumor, comprising administering a cytostatic compound according to formula I, II or III
wherein
A is carbonyl, methylene, hydroxymethinyl, alkoxymethinyl, aminomethinyl, oxime, hydrazone, arylhydrazone, or semicarbazone;
B if present is CR 25 R 26 , O, S or NR 27 ;
R 1 , R 3 , R 4 , R 8 , R 10 , and R 11 are independently hydrogen, hydroxyl, alkoxy, halogen or C 1 to C 6 alkyl;
R 2 and R 7 are independently halogen, hydroxyl or hydrogen,
R 5 if present is hydroxyl, phosphate, hydrogen, halogen, alkyl, cycloalykyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio or amino;
R 6 if present is hydrogen or C 1 to C 6 alkyl;
R 9 is nitro, hydrogen, hydroxyl, amino, halogen, alkyl, alkenyl, alkynyl, or aryl; and
R 21 , R 22 , R 23 , and R 24 , if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl;
R 25 and R 26 if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl; and
R 27 if present is hydrogen or C 1 to C 6 alkyl;
or salt thereof;
and an alkylating agent to a subject.
2. The method of claim 1 , wherein the alkylating agent is an O 6 -alkylating agent.
3. The method of claim 1 , wherein the alkylating agent has a structure according to formula IV
wherein
X and Y are independently carbonyl, methylene, hydroxymethinyl, alkoxymethinyl, aminomethinyl, oxime, hydrazone, arylhydrazone or semicarbazone,
R 31 is alkyl, hydrogen, alkoxy, alkenyl, alkynyl, cycloalkyl or aryl; and
R 32 is amino, hydrogen, hydroxyl or halogen
or salt thereof.
4. The method of claim 1 , wherein the cytostatic compound is niclosamide.
5. The method of claim 1 , wherein the alkylating agent is temozolomide.
6. The method of claim 4 , wherein the molar ratio between niclosamide and temozolomide is in the range of 10% niclosamide/90% temozolomide to 90% niclosamide/10% temozolomide.
7. The method of claim 1 , wherein the solid tumor is glioblastoma.
8. The method of claim 7 , wherein the glioblastoma is primary glioblastoma, de novo glioblastoma, secondary glioblastoma, recurrent glioblastoma, glioblastoma with increased methylation of the promoter of the gene O6-Methylguanin-Methyltransferase (MGMT), glioblastoma without increased methylation of the promoter of MGMT, glioblastoma with mutated p53, glioblastoma without mutated p53, glioblastoma with alterations of the gene encoding kappa light polypeptide gene enhancer in B-cells inhibitor (NFκBIA), glioblastoma without alterations of the gene encoding NFκBIA, glioblastoma with alterations of the gene encoding epidermal growth factor receptor (EGFR), glioblastoma without alterations of the gene encoding EGFR, glioblastoma with alterations of the gene encoding platelet-derived growth factor receptor (PDGFRA), glioblastoma without alterations of the gene encoding PDGFRA, glioblastoma with alterations of the gene encoding isocitrate dehydrogenase 1 (IDHI), glioblastoma without alterations of the gene encoding IDHI, glioblastoma with alterations of the gene encoding neurofibromatosis type 1 (NF1) or glioblastoma without alterations of the gene encoding NF1.
9. The method of claim 1 , wherein the compounds are formulated for simultaneous or subsequent administration.
10. The method of claim 9 , wherein the formulation for simultaneous administration is a mixture of the two compounds.
11. The method of claim 1 , wherein the cytostatic compound is formulated for resorption into the central nervous system.
12. A pharmaceutical composition comprising a cytostatic compound according to formula I, II or III
wherein
A is carbonyl, methylene, hydroxymethinyl, alkoxymethinyl, aminomethinyl, oxime, hydrazone, arylhydrazone, or semicarbazone;
B if present is CR 25 R 26 , O, S or NR 27 ;
R 1 , R 3 , R 4 , R 8 , R 10 , and R 11 are independently hydrogen, hydroxyl, alkoxy, halogen or C 1 to C 6 alkyl;
R 2 and R 7 are independently halogen, hydroxyl or hydrogen,
R 5 if present is hydroxyl, phosphate, hydrogen, halogen, alkyl, cycloalykyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio or amino;
R 6 if present is hydrogen or C 1 to C 6 alkyl;
R 9 is nitro, hydrogen, hydroxyl, amino, halogen, alkyl, alkenyl, alkynyl, or aryl; and
R 21 , R 22 , R 23 , and R 24 , if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl;
R 25 and R 26 if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl; and
R 27 if present is hydrogen or C 1 to C 6 alkyl:
or salt thereof;
an alkylating agent;
and a pharmaceutically acceptable excipient.
13. A method of treating a solid tumor characterized by a decreased expression level of NFκBIA, comprising administering a cytostatic compound according to formula I, II or III
to a subject, wherein
A is carbonyl, methylene, hydroxymethinyl, alkoxymethinyl, aminomethinyl, oxime, hydrazone, arylhydrazone, or semicarbazone;
B if present is CR 25 R 26 , O, S or NR 27 ;
R 1 , R 3 , R 4 , R 8 , R 10 , and R 11 are independently hydrogen, hydroxyl, alkoxy, halogen or C 1 to C 6 alkyl;
R 2 and R 7 are independently halogen, hydroxyl or hydrogen,
R 5 if present is hydroxyl, phosphate, hydrogen, halogen, alkyl, cycloalykyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio or amino;
R 6 if present is hydrogen or C 1 to C 6 alkyl;
R 9 is nitro, hydrogen, hydroxyl, amino, halogen, alkyl, alkenyl, alkynyl, or aryl; and
R 21 , R 22 , R 23 , and R 24 , if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl;
R 25 and R 26 if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl; and
R 27 if present is hydrogen or C 1 to C 6 alkyl.
14. A method for determining if therapy with a cytostatic compound according to formula I, II or III
wherein
A is carbonyl, methylene, hydroxymethinyl, alkoxymethinyl, aminomethinyl, oxime, hydrazone, arylhydrazone, or semicarbazone;
B if present is CR 25 R 26 , O, S or NR 27 ;
R 1 , R 3 , R 4 , R 8 , R 10 , and R 11 are independently hydrogen, hydroxyl, alkoxy, halogen or C 1 to C 6 alkyl;
R 2 and R 7 are independently halogen, hydroxyl or hydrogen,
R 5 if present is hydroxyl, phosphate, hydrogen, halogen, alkyl, cycloalykyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio or amino;
R 6 if present is hydrogen or C 1 to C 6 alkyl;
R 9 is nitro, hydrogen, hydroxyl, amino, halogen, alkyl, alkenyl, alkynyl, or aryl; and
R 21 , R 22 , R 23 , and R 24 , if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl;
R 25 and R 26 if present are independently hydrogen, hydroxyl, halogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl; and
R 27 if present is hydrogen or C 1 to C 6 alkyl,
is suitable for treating a patient with a solid tumor comprising the steps of
a) determining the expression level of NFκBIA in a sample of tumor cells or tumor tissue of the patient;
b) comparing the determined expression level with a reference value;
c) determining if the therapy with niclosamide is suitable for the patient based on the result of the comparison of step b), wherein underexpression or a deletion of NFκBIA indicates that the combination therapy is suitable for the patient.
15. A method for determining the molar ratio of niclosamide to temozolomide to be administered to a patient with a solid tumor comprising the steps of
a) determining the expression level of NFκBIA in a sample of tumor cells or tumor tissue of the patient;
b) comparing the determined expression level with a reference value;
c) determining the molar ratio of niclosamide to temozolomide based on the result of the comparison of step b), wherein
(i) an expression above the reference value indicates that the molar ratio shall be below 40% niclosamide; and
(ii) an expression level below the reference value indicates that the molar ratio shall be equal to or larger than 40% niclosamide.
16. The method of claim 13 , wherein the solid tumor is glioblastoma.
17. The method of claim 16 , wherein the glioblastoma is primary glioblastoma, de novo glioblastoma, secondary glioblastoma, recurrent glioblastoma, glioblastoma with increased methylation of the promoter of the gene O6-Methylguanin-Methyltransferase (MGMT), glioblastoma without increased methylation of the promoter of MGMT, glioblastoma with mutated p53, glioblastoma without mutated p53, glioblastoma with alterations of the gene encoding kappa light polypeptide gene enhancer in B-cells inhibitor (NFκBIA), glioblastoma without alterations of the gene encoding NFκBIA, glioblastoma with alterations of the gene encoding epidermal growth factor receptor (EGFR), glioblastoma without alterations of the gene encoding EGFR, glioblastoma with alterations of the gene encoding platelet-derived growth factor receptor (PDGFRA), glioblastoma without alterations of the gene encoding PDGFRA, glioblastoma with alterations of the gene encoding isocitrate dehydrogenase 1 (IDHI), glioblastoma without alterations of the gene encoding IDHI, glioblastoma with alterations of the gene encoding neurofibromatosis type 1 (NF1) or glioblastoma without alterations of the gene encoding NF1.